Kathrine Andreassen - Navamedic ASA Chief Executive Officer
| NAVA Stock | NOK 22.80 0.20 0.88% |
CEO
Ms. Kathrine Gamborg Andreassen was appointed Chief Executive Officer at NAVAMEDIC ASA effective as of January 1, 2019. She was Chairman of the Board from June 7, 2018 till December 20, 2018. Gamborg Andreassen was the CEO of Weifa ASA until the company was acquired by Karo Pharma AB in November 2017, and also served as VP Consumer Health at Weifa. Gamborg Andreassen is the coowner and Chair of the Board at Novicus Pharma AS. She holds a Msc in Business Strategy Marketing from the University of Wisconsin at Madison and a BBA from HandelsakademietOslo Business School. since 2019.
| Age | 57 |
| Tenure | 6 years |
| Phone | 47 67 11 25 40 |
| Web | https://www.navamedic.com |
Navamedic ASA Management Efficiency
The company has return on total asset (ROA) of 0.0633 % which means that it generated a profit of $0.0633 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.073 %, meaning that it generated $0.073 on every $100 dollars invested by stockholders. Navamedic ASA's management efficiency ratios could be used to measure how well Navamedic ASA manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 2 records | CEO Age | ||
| Ronny Skuggedal | PCI Biotech Holding | 47 | |
| Daniel Schneider | Photocure | N/A | |
Management Performance
| Return On Equity | 0.073 | |||
| Return On Asset | 0.0633 |
Navamedic ASA Leadership Team
Elected by the shareholders, the Navamedic ASA's board of directors comprises two types of representatives: Navamedic ASA inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Navamedic. The board's role is to monitor Navamedic ASA's management team and ensure that shareholders' interests are well served. Navamedic ASA's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Navamedic ASA's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Lars Hjarrand, Chief Financial Officer | ||
| PerAnders Elvertro, Chief Commercial Officer, Head of Regulatory Affairs and Drug Safety | ||
| Astrid Bratvedt, Chief Officer | ||
| Jostein Davidsen, Director | ||
| Mattias Hartmann, Marketing Director | ||
| Kathrine Andreassen, Chief Executive Officer | ||
| Narve Reiten, Director | ||
| Inger Solberg, Director | ||
| Mattias Haartman, Marketing & Sales Director | ||
| Ole Eriksen, Chief Officer | ||
| Magnus Emmoth, Chief Executive Officer of Navamedic Medtech AB | ||
| Terje Bakken, Chairman of the Board | ||
| Cheng Lu, Director |
Navamedic Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Navamedic ASA a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.073 | |||
| Return On Asset | 0.0633 | |||
| Profit Margin | 0.03 % | |||
| Operating Margin | 0.1 % | |||
| Current Valuation | 578.31 M | |||
| Shares Outstanding | 16.35 M | |||
| Shares Owned By Insiders | 41.56 % | |||
| Shares Owned By Institutions | 14.08 % | |||
| Price To Earning | 9.39 X | |||
| Price To Book | 3.04 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in Navamedic Stock
Navamedic ASA financial ratios help investors to determine whether Navamedic Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Navamedic with respect to the benefits of owning Navamedic ASA security.